NervGen Pharma (NGEN) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NervGen Pharma (NGEN) has outperformed Veraxa Biotech (VRXA) over the past year, losing 48.2% versus a loss of 89.6%. NervGen Pharma is the larger company by market cap ($185.5 million vs $185.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NGEN | VRXA |
|---|---|---|
| Share price | $1.73 | $1.31 |
| Market cap | $185.48M | $185.10M |
| 1-day change | -1.43% | +20.09% |
| YTD return | -68.75% | -89.78% |
| 1-year return | -48.18% | -89.58% |
| 5-year return | -7.41% | — |
| EPS (TTM) | $-0.57 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.30 | $27.36 |
| 52-week low | $1.58 | $1.04 |
| Distance from 52-week high | -72.62% | -95.22% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +479.71% | — |
| Average volume | 565.19K | 267.20K |
| Shares outstanding | 107.52M | 141.41M |
| Employees | 9 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGEN has outperformed VRXA by 41.4 percentage points over the past year.
About NervGen Pharma
NGEN stock →NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
NGEN vs VRXA FAQ
Which is bigger, NervGen Pharma or Veraxa Biotech?
NervGen Pharma (NGEN) is larger, with a market capitalization of $185.48M compared with $185.10M for Veraxa Biotech (VRXA).
Which stock has performed better over the past year, NGEN or VRXA?
NGEN returned -48.18% over the past 12 months, compared with -89.58% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are NervGen Pharma and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.